Tirzepatide — Complete Clinical Guide
Tirzepatide: mechanism, indications (Mounjaro, Zepbound), dosing, adverse effects, contraindications and compounded availability.
Evidence-based answer
Tirzepatide: mechanism, indications (Mounjaro, Zepbound), dosing, adverse effects, contraindications and compounded availability.
Regulatory status: Tirzepatide is FDA approved as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes. Compounded tirzepatide is not an FDA-approved finished product.
How it works
Tirzepatide activates both GIP and GLP-1 receptors. The combined incretin effect reduces appetite and energy intake, slows gastric emptying most strongly during initiation, and improves glucose-dependent insulin signaling.
Mechanism is context, not proof. A defensible claim requires human outcome data for the exact molecule, formulation, dose and population. Receptor activity alone cannot establish how much weight a patient will lose, whether an injury will heal or whether a compounded vial has the identity and potency of a trial product.
What the clinical evidence shows
In SURMOUNT-1, adults without diabetes receiving 5, 10 or 15 mg weekly achieved mean weight changes of about −15.0%, −19.5% and −20.9% at 72 weeks, versus −3.1% with placebo. In the 751-person SURMOUNT-5 head-to-head trial, tirzepatide produced −20.2% mean weight change versus −13.7% with semaglutide at 72 weeks.
| Study or evidence level | Population | Intervention | Main result | Interpretation |
|---|---|---|---|---|
| SURMOUNT-1 | 2,539 adults without diabetes | 5, 10 or 15 mg weekly | −15.0%, −19.5%, −20.9% at 72 weeks | Placebo −3.1%; lifestyle intervention in all groups |
| SURMOUNT-5 | 751 adults without diabetes | Tirzepatide 10/15 mg vs semaglutide 1.7/2.4 mg | −20.2% vs −13.7% at 72 weeks | Open-label; manufacturer funded |
Clinical-use framework
Zepbound starts at 2.5 mg weekly for four weeks, then 5 mg weekly. Increases are made in 2.5 mg steps after at least four weeks based on response and tolerability; approved maintenance doses are 5, 10 or 15 mg weekly.
A safe plan includes medical history, medication reconciliation, pregnancy screening where relevant, contraindication review, a written titration or administration schedule, missed-dose instructions, side-effect escalation and follow-up. Laboratory testing is individualized; a universal panel is not evidence-based for every patient, but clinicians may order testing based on symptoms, comorbidities and the medicine considered.
How to evaluate an online program
- Identify the legal entities. The marketing company, prescribing practice and dispensing pharmacy may be different organizations.
- Confirm the clinician. Look for a full name, credential, NPI where applicable and authority to practice in the patient’s state.
- Read the prescription label. Verify the exact drug, salt or base, concentration, directions, facility and beyond-use date.
- Normalize cost. Add medication, membership, visits, labs, supplies, shipping and dose surcharges.
- Match the evidence. Ask whether the offered dose and route were studied for the claimed outcome.
- Review continuity. Understand refills, cold-chain handling, replacement, pharmacy changes and cancellation.
Safety
Common adverse effects are gastrointestinal—nausea, diarrhea, vomiting, constipation and abdominal symptoms. Labeling includes a boxed warning regarding thyroid C-cell tumors observed in rodents and cautions involving pancreatitis, gallbladder disease, kidney injury related to dehydration, hypoglycemia with certain diabetes drugs and severe gastrointestinal disease.
This page is educational and does not replace diagnosis or individualized prescribing. Severe symptoms, suspected overdose or a serious allergic reaction require urgent in-person evaluation.
Frequently asked questions
Is tirzepatide FDA approved?
Tirzepatide is FDA approved as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes. Compounded tirzepatide is not an FDA-approved finished product.
What is the strongest evidence for tirzepatide?
In SURMOUNT-1, adults without diabetes receiving 5, 10 or 15 mg weekly achieved mean weight changes of about −15.0%, −19.5% and −20.9% at 72 weeks, versus −3.1% with placebo. In the 751-person SURMOUNT-5 head-to-head trial, tirzepatide produced −20.2% mean weight change versus −13.7% with semaglutide at 72 weeks.
Can a compounded or microdose product claim the same trial result?
Not automatically. The trial result applies most directly to the studied product, dose, titration, population and duration. A different formulation, route or lower dose requires its own evidence.
What should be verified before treatment?
Verify the exact product, indication, prescriber, pharmacy, concentration, dose schedule, recurring cost, commitment, follow-up plan and urgent-care instructions.
Primary sources
- Zepbound prescribing information Primary clinical or regulatory source
- SURMOUNT-1, NEJM Primary clinical or regulatory source
- SURMOUNT-5, NEJM Primary clinical or regulatory source
Provider marketing can document what is offered; it is not used as proof of safety or comparative effectiveness. Evidence was reviewed through July 12, 2026.